Segment Information

12 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Information

14. Segment Information

The Company operates the business on the basis of a single reportable segment, which is the business of discovery, development and commercialization of novel therapeutics for chronic diseases. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the company as a single operating segment.

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the United States; therefore, total revenues for fiscal 2013, 2012, and 2011 are attributed to the United States. All long-lived assets at September 30, 2013 and 2012 are located in the United States.

The Company sells NUEDEXTA to a limited number of wholesalers. Three wholesalers accounted for 88%, 89% and 91% of gross product sales in fiscal 2013, 2012 and fiscal 2011, respectively. In addition, the three wholesalers accounted for 91% of trade receivables at September 30, 2013 and 2012.

Less than 10% of the Company’s total revenues in fiscal 2013 and 2012 were derived from a license agreement with GSK and the sale of rights to royalties under that agreement. Royalties from GSK were approximately 37% of total revenues in fiscal 2011.